Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization by Reinen, J. et al.
ORIGINAL PAPER
Reversed-phase liquid chromatography coupled on-line
to estrogen receptor bioaffinity detection based
on fluorescence polarization
Jelle Reinen & Jeroen Kool & Nico P. E. Vermeulen
Received: 25 September 2007 /Revised: 1 January 2008 /Accepted: 7 January 2008 /Published online: 31 January 2008
# The Author(s) 2008
Abstract We describe the development and validation of a
high-resolution screening (HRS) platform which couples
gradient reversed-phase high-performance liquid chromatog-
raphy (RP-HPLC) on-line to estrogen receptor α (ERα)
affinity detection using fluorescence polarization (FP). FP,
which allows detection at high wavelengths, limits the
occurrence of interference from the autofluorescence of test
compounds in the bioassay. A fluorescein-labeled estradiol
derivative (E2-F) was synthesized and a binding assay was
optimized in platereader format. After subsequent optimiza-
tion in flow-injection analysis (FIA) mode, the optimized
parameters were translated to the on-line HRS bioassay.
Proof of principle was demonstrated by separating a mixture
of five compounds known to be estrogenic (17β-estradiol,
17α-ethinylestradiol and the phytoestrogens coumestrol,
coumarol and zearalenone), followed by post-column bio-
affinity screening of the individual affinities for ERα. Using
the HRS-based FP setup, we were able to screen affinities of
off-line-generated metabolites of zearalenone for ERα. It is
concluded that the on-line FP-based bioassay can be used to
screen for the affinity of compounds without the disturbing
occurrence of autofluorescence.
Keywords Fluorescence polarization . High-resolution
screening (HRS) . Estrogen receptorα . Phytoestrogens .
On-line bioaffinity assay . Receptor affinity detection (RAD)
Introduction
In recent years, the presence of endocrine-disrupting com-
pounds (EDCs) in the environment has become amajor issue of
concern in view of their effects on both human health and
ecosystem integrity. The classes of substances that possess
estrogenic activities include diverse manmade and natural
chemicals (e.g., pesticides, plasticizers, polychlorinated biphe-
nyls, phytoestrogens, natural hormones) and pharmaceuticals
(e.g., ethinylestradiol, tamoxifen) [1, 2]. EDCs can interfere
with the endocrine system by binding to the estrogen recep-
tors α (ERα) or β (ERβ) and mimicking the action of the
naturally produced hormone estrogen or blocking the receptor
for this hormone in target cells, thereby preventing its action [3].
Therefore, it is important to screen compounds and compound
mixtures for their ability to bind to one of these receptors.
Alternatively, the task of screening for compounds containing
estrogenic and antiestrogenic properties is also very important
from medical and pharmaceutical points of view [4].
Several biodetection methodologies have meanwhile been
developed to determine the bioaffinities of ligands towards
ERα. These assays include relatively cumbersome radio-
ligand binding assays [5], fluorescence enhancement based
assays [6] and fluorescence polarization (FP) based binding
assays [7]. A major drawback of these assays is that, in the
presence of cross-reactive compounds, the response provided
by the bioassay reflects the sum of the concentrations of all
individual compounds and their affinities for the ERα.
Moreover, matrix components, which are sometimes present
in far higher concentrations than the analyte(s), interfere with
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the binding assay signals, thereby leading to false-positive or
false-negative results [8]. Therefore, none of these methods
can be applied for the identification of individual ERα
binding ligands in mixtures of compounds, as is the case
with natural compound extracts, biological samples contain-
ing different EDCs, and drug metabolite mixtures.
However, the introduction of the on-line high-resolution
screening (HRS) technology enabled the screening of
individual compounds in mixtures by coupling a separation
technology, usually gradient HPLC, to post-column bio-
chemical detection assays on-line [9–14]. Oosterkamp et al.
[10] developed a HRS system to screen mixtures for
compounds with an affinity for ERα. A similar setup has
been used to screen natural plant product extracts for ERα
and ERβ binding activity [15] and to identify and screen
cytochrome P450-derived metabolites of tamoxifen with
ERα affinity [2, 16]. The reported HRS ERα bioaffinity
assays are based on the increase of the fluorescent signal of
the tracer compound coumestrol upon binding to the ERα
ligand binding domain (LBD). When the tracer is displaced
by a compound with ERα affinity that elutes from the
HPLC column, it is seen as a negative peak in the baseline
of the ERα bioassay. Coumestrol, the fluorescent probe,
has short excitation (340 nm) and emission (410 nm)
wavelengths when bound to the ERα LBD [6]. Since there
are many potentially interfering fluorescent compounds that
can be excited at 300–350 nm and emit at 360–430 nm in
biomatrices, coumestrol is not appropriate for the precise
and selective detection of EDCs in biosamples containing
phytoestrogens such as flavonoids, coumestans or lignans.
One solution to this problem is to use another tracer
compound, thus making it possible to monitor the bioassay
signal at higher excitation and emission wavelengths.
However, no tracer compounds are currently available
which also display the necessary fluorescence enhancement
upon binding to the ERα, thus making it impossible to use
them in a HRS ERα setup. Another option is fluorescence
polarization (FP) detection. FP is based upon the principle
that interaction of a receptor with a fluorophore-containing
ligand increases the effective size of the fluorophore
through the formation of a receptor ligand complex. The
increase in effective size reduces the rate of fluorophore
rotation and increases the polarization over that of the
unbound fluorophore [7]. FP instruments measure the rate
of fluorophore rotation in solution rather than fluorescence
intensity [17]. The polarization value is independent of the
fluorophore concentration and intensity and has the
advantage that it is minimally affected by autofluorescence,
solution opacity or color, and is more tolerant to fluores-
cence quenching and light scattering [18].
The objective of the present study was to develop and
evaluate the use of FP detection in combination with the on-
line HRS technology to provide information about the ERα
affinities of individual compounds in complex mixtures. The
assay is based on competition for the ERα LBD between
eluting compounds and a fluorescein-labeled estradiol deriv-
ative (E2-F), which was synthesized based on tracer structures
described by Parker et al. [7] and Ohno et al. [19] for off-line
FP-based ER assays. After synthesis of the tracer E2-F, the
ERα binding assay was first optimized in FP platereader
format and subsequently transferred to flow-injection analy-
sis (FIA) mode with FP detection by using an on-line FP
detector cell, which was recently constructed by Kool et al.
[20] to measure GPCR-mediated modulation of cAMP
production. Finally, after optimization of the assay in FIA
mode, the on-line FP detection system was coupled to a
gradient HPLC system. In this so-called HRS setup we
separated mixtures of known estrogenic compounds—e.g.,
17β-estradiol, 17α-ethinylestradiol and the phytoestrogens
coumestrol, coumarol and zearalenone—and screened the
individual compounds for ERα affinities. We also showed
that this HRS ERα-FP system was suitable for screening off-
line-generated cytochrome P450 (Cyt P450) metabolites of
zearalenone for ERα affinity. We conclude that we were able
to incorporate an on-line FP detector cell into a HRS system
to screen for the ERα affinities of individual compounds in
complex mixtures without incurring interference from the
autofluorescence of the compounds.
Materials and methods
Materials
Tween 20, 17β-estradiol (E2), estrone (E1), 17α-ethinyl
estradiol (EE2), diethylstilbestrol (DES), estriol, zearale-
none, fluorescein-5-isothiocyanate (5-FITC) and coumes-
trol were obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands). ELISA blocking reagent was purchased from
Roche (Mannheim, Germany). Dry THF was freshly dis-
tilled from LiAlH4. All other chemicals were of analytical
grade and obtained from standard suppliers.
Synthesis
Fluorescein-labeled estradiol derivative (E2-F) The fluo-
rescein-labeled estradiol derivative (E2-F) was synthesized
in analogy to methods described previously [7, 19] from
estrone as the starting material (Fig. 1). To a solution of
estrone (1, 700 mg, 2.59 mmol) in dry DMF (3 mL),
imidazole (250 mg) was added. Subsequently, tert-butyl
dimethylsilyl chloride (tBDSC) dissolved in dry THF
(2 mL) was slowly added and the reaction mixture was
stirred at room temperature for 3 h. The resulting cloudy
white mixture was extracted with ethyl acetate (EtOAc).
The organic extract was washed with water once, with brine
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twice and then with water once again. The organic extract
was dried over MgSO4, filtered, and concentrated by rotary
evaporation at 45 °C. Recrystallization was performed
using a mixture of 15 mL MeOH and 5 mL DCM to afford
2 (667.2 mg, 67%). Under an atmosphere of dry nitrogen,
3-butyn-1-ol (1.35 g) was dissolved in dry THF (27 mL)
and cooled to −78 °C. n-Butyllithium (BuLi) in hexane
(16.9 mL, 0.027 mol) was added dropwise at −78 °C.
Compound 2 (3.60 g, 9.36 mmol) dissolved in dry THF
(25 mL) was carefully added dropwise at −78 °C and the
solution was allowed to warm to room temperature and was
thereafter stirred at 40 °C for an additional 60 min. The
remaining BuLi was neutralized by carefully adding 5 mL
EtOAc/MeOH (1:1). Extraction was performed with
EtOAc, as described above. The crude product was purified
by column chromatography on silica gel (10% EtOAc in
hexane) to afford 3 (1.62 g, 38%). To a solution of 3 (1.6 g,
3.52 mmol) dissolved in dry THF (25 mL) was added
triethylamine (TEA, 718 μL) followed by MeSO2Cl
(395 μL, 5.1 mmol) while stirring at 0 °C. Afterwards the
solution was allowed to warm to room temperature. After
10 h the reaction mixture was extracted with DCM. The
organic extract was treated as described above and
concentrated by rotary evaporation to afford 4 (1.80 g,
96%). Under an atmosphere of dry nitrogen, NaN3 (8.0 g)
was added to a solution of 4 (1.80 g, 3.38 mmol) dissolved
in dry DMPU (25 mL) while stirring rapidly. After stirring
the solution for three days, the resulting reaction mixture
was extracted with EtOAc as described above to afford 5
(1.36 g, 84%). To a solution of 5 (1.36 g, 2.83 mmol) in
MeOH (70 mL) and TEA (16 mL), 1,3-propane dithiol
(12 mL) was added. The solution was stirred o/n at room
temperature and was concentrated by rotary evaporation.
The concentrated solution dissolved in 100 mL hexane was
purified by column chromatography on silica gel. Elution of
the purified product 6 (1.08 g, 84%) was performed using
EtOAc/MeOH (1:1). To remove the protective tert-butyl
dimethylsilyl group, TBAF.H2O (300 mg) was added to a
solution of 6 (258 mg, 0.57 mmol) dissolved in dry THF
(4 mL) at 0 °C. After stirring for 1 h and allowing the
solution to warm to room temperature, the crude product
was extracted with DCM. The product was purified with
Flash Master chromatography with an EtOAc/MeOH
gradient to afford 7 (176 mg, 91%). Fluorescein-5-
isothiocyanate (5-FITC, 7 mg, 17.8 μmol) was added to a
solution of 7 (5 mg, 14.7 μmol) dissolved in dry DMF
(500 μL) and dry pyridine (25 μL). The solution was stirred
o/n in the dark at room temperature. The crude product was
extracted with DCM and purified first with Flash Master
chromatography (silicagel-based; EtOAC/MeOH gradient)
and then with preparative C18 HPLC to afford 8 (E2-F,
8.02 mg, 75%). 1H NMR (400.13 MHz, CD3OD): δ 8.04
(1 H, d, J=1.9 Hz), 7.70 (1 H, dd, J=8.2, 1.9 Hz), 7.10
(1 H, d, J=8.2 Hz), 7.01 (1 H, d, J=8.5 Hz), 6.89 (1 H, d,
J=8.9 Hz), 6.88 (1 H, d, J=8.9 Hz), 6.66 (2 H, d, J=
2.3 Hz), 6.58 (2 H, dd, J=8.9, 1.9 Hz), 6.47 (1 H, dd, J=
8.5, 2.6 Hz), 6.42 (1 H, d, J=2.6 Hz), 3.80 (2 H, t,
J=6.6 Hz), 2.70 (1 H, d, J=1.9 Hz), 2.65 (2 H, t, J=
6.6 Hz), 2.1–2.3 (3 H, m), 1.9–2.0 (2 H, m), 1.65–1.85
(4 H, m), 1.25–1.50 (5 H, m), 0.85 (3 H, s). ESI-MS: m/z
729 (M + H)+.
7-Hydroxy-3-p-hydroxyphenylcoumarine (coumarol) The
synthesis of coumarol was analogous to the synthesis of
benzene-hydroxylated-3-aryl-coumarins described by Buu-
Hoi et al. [21]. Briefly, 2,4-dimethoxybenzaldehyde was
reacted with p-methoxyphenyl-acetonitrile to form α-p-
methoxyphenyl-β-(2,4-dimethoxyphenyl)-acrylonitrile. The
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Fig. 1 Synthesis of a fluorescein-labeled estradiol (E2-F) derivative (for abbreviations, see “Experimental” section)
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formed product formed was demethylated using pyridine
hydrochloride to form the final product coumarol. 1H NMR
(400.13 MHz, DMSO-d6): δ 10.57 (1 H, s), 9.68 (1 H, s),
8.00 (1 H, s), 7.56 (1 H, d, J=8.6 Hz), 7.53 (2 H, d, J=
8.7 Hz), 6.81 (2 H, d, J=8.7 Hz), 6.80 (1 H, dd, J=10.8,
2.7 Hz), 6.73 (1 H, d, J=2.2 Hz). ESI-MS: m/z 255 (M + H)+.
Biomaterials
Microsomes Rat liver microsomes were prepared from
phenobarbital (PB)-induced rat liver, as described previous-
ly by Roosenboom et al. [22].
Estrogen receptor α The ERα ligand binding domain
(LBD) was expressed in Escherichia coli according to the
method of Eiler et al. [23], but without estradiol in the
medium. The concentration of ERα LBD (250 nM) was
measured by determining the Bmax value (by titration with
radiolabeled estradiol) [24]. The Bmax value was measured
as the maximum amount of ligand binding extrapolated to a
very high concentration of ligand.
Microsomal incubations
Microsomal PB-induced rat liver incubations were carried out
in a total volume of 500 μL. The reaction mixture consisted of
2.5 mM MgCl2 in 100 mM potassium phosphate buffer (pH
7.4), 100 μM zearalenone and 2.6 mg/mL rat liver micro-
somes. The reactions were initiated by the addition of a
NADPH regenerating system, resulting in final concentrations
of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and
0.4 U/mL glucose-6-phosphate dehydrogenase. Incubation
was carried out at 37 °C for 120 min and the reaction was
terminated by the addition of 50 μL 10% HClO4. Following
centrifugation at 14,000 rpm for 10 min, 450 μL of super-
natant was applied to a strata_X 33 μm Polymeric Sorbent
200 mg / 3 mL (Phenomenex, Amstelveen, The Netherlands)
column for SPE sample preparation. Before sample applica-
tion the column was conditioned with 2 mL MeOH and
subsequently equilibrated with 2 mL H2O. The sample was
washed with 2 mL 5% (v/v) of aqueous methanol and elution
was performed using 2 mL 50% (v/v) of MeOH in ACN.
After evaporation, the residues were dissolved in 1 mL 40%
(v/v) of aqueous methanol.
Instrumentation
A NOVOstar+ microplate fluorometer from BMG LABTECH
GmbH (Offenburg, Germany) was used for the FP-based
microplate reader assay. The excitation wavelength was set at
485 nm, the emission wavelength at 520 nm. Black-bottomed
PP-96-well microtiter plates from Greiner Bio-one (Alphen
a/d Rijn, The Netherlands) were used for all microplate reader
experiments.
The setup we used was adapted from the homogeneous
coumestrol-based ERα affinity detection system described
by Kool et al. [2]. For the on-line FP assay, two Knauer
K-500 HPLC pumps (Berlin, Germany) were used to control
the 120-mL superloops, made in-house, containing receptor
(ERα) and tracer ligand (E2-F), respectively, and one
Knauer K-500 HPLC pump was used to deliver the injected
samples. The ERα and E2-F solutions were prepared in
sodium phosphate buffer (10 mM; pH 7.4) containing
150 mM NaCl and 0.4 mg/mL ELISA blocking reagent.
Both superloops were kept on ice. Flow restrictors were
inserted between the pumps and the superloops to ensure
proper operation of the pumps at low flow rates. The flow
restrictors consisted of natural PEEK tubing and resulted in
back pressures of approximately 50 bar. The pressure limits
of the pumps were set 20 bar higher than the working
pressure, and VICI Jour backpressure regulators (Schenkon,
Switzerland) were inserted after the superloops to prevent
damage from possible clogging of the system. A Gilson 234
autoinjector (Villiers-le-Bel, France) equipped with a Rheo-
dyne (Bensheim, Germany) six-port injection valve (different
injection loops) was used to inject samples. To maintain the
reaction coils at a constant temperature, a Shimadzu CTO-
10AC column oven (Duisburg, Germany) was integrated into
the system. An Agilent 1100 (Waldbronn, Germany) series
fluorescence detector (λex 498 nm; λem 522 nm) was used to
monitor fluorescence polarization, as described by Kool et
al. [20]. Briefly, the standard 8 μL FLD cell was modified
with parallel-placed (both mounted in the detector cell)
fluorescence polarization filters from Melles Griot (Didam,
The Netherlands). One filter (12.5 mm visible pol. 350–
650 nm 03FPG019) was placed in the pathway of the
excitation beam and one (Mount. Sheet Pol. 20.D- 16.9CA
03FPG001) in the pathway of the emission beam. All hard-
ware was integrated into one HRS system by Kiadis B.V.
(Groningen, the Netherlands), and was controlled by
software developed by Kiadis B.V.
Coumestrol-based microplate reader assay of ERα affinity
The microplate reader assay for determining ERα binding
based on the competition between fluorescent coumestrol and
estrogenic compounds previously described by Gurer-Orhan et
al. [6] was used to plot a competitive binding curve for E2-F.
FP-based microplate reader assay of ERα affinity
The microplate reader assay was used to optimize the FP
ERα receptor affinity detection (RAD) system in FIA and
HPLC modes. This assay is based on the competition
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between estrogenic compounds and the newly synthesized
fluorescein-labeled estradiol derivative (E2-F) for binding
to the ERα LBD. Displacement of E2-F was measured as
the decrease in fluorescence polarization intensity. Different
concentrations of E2-F tracer were tested first. Since Tween
20, a detergent also used by Kool et al. in their coumestrol-
based HRS ERα assay [2], can improve the resolution of
the assay in HRS mode, and since organic modifiers are
necessary for the optimal performance of the gradient
HPLC system, the next step in the optimization process was
to vary these parameters. The experiments were carried out
at 24 °C with well volumes of 250 μL binding buffer
[potassium phosphate buffer (10 mM; pH 7.4) containing
0.4 mg/ml ELISA blocking reagent]. The ERα LBD was
introduced into the binding assay buffer at a final
concentration of 1.64 nM. The E2-F stock solution was
prepared in DMSO and dilutions were made in binding
buffer. Concentrations ranging from 0.42 nM to 3.31 μM
were investigated for E2-F optimization. For the experi-
ments to investigate the detergent and organic modifier
effects, the final concentration of E2-F in the assay was
83.3 nM. Aliquots of 25 μL of organic modifier or deter-
gent at various concentrations were pipetted into a 96-well
plate that already contained either 75 μL binding buffer
(equal to 0% displacement) or 75 μL 33.3 μM E2 in
binding buffer (equal to 100% displacement). The 96-well
plate was gently but thoroughly mixed after pipetting 75 μL
E2-F into each well. Finally, 75 μL of the ERα LBD was
pipetted into the wells. After an incubation time of 60 min
at room temperature, the fluorescence polarization (FP) was
recorded at 485 nm excitation and 520 nm emission. All
experiments were performed in quadruplicate. The differ-
ence in FP (ΔFP) was calculated by subtracting the FP
value found at 100% displacement from the FP value found
when no E2 was present under different conditions.
FP-based ERα receptor affinity detection (RAD)
in flow-injection analysis (FIA) mode
A schematic overview of the RAD system in FIA mode is
depicted in Fig. 2. In this system the flow from a superloop
containing ERα LBD is continuously mixed with flow
from a superloop containing E2-F. Compound samples
(10 μL) are introduced into the system by flow injection
into a carrier solution (100 μL/min). During optimization,
the carrier solution was water. Injected compounds and
ERα, added to the carrier stream via an inverted Y-type
mixing union at a flow rate of 100 μL/min, were allowed to
bind in a Tefzel reaction coil (25 μL). This mixture
was combined with the flow of the E2-F solution of
100 μL/min. The final equilibrium between ERα, com-
pound, and E2-F was established in a knitted 0.5 mm i.d.
PTFE reaction coil (250 μL). The temperatures of both
reaction coils were maintained constant at 37 °C. Fluores-
cence polarization (FP) detection took place directly after
the second reaction coil. When the binding of E2-F is
decreased due to competition from an eluting ERα ligand,
depolarization occurs. This decrease in fluorescence polari-
zation is a measure of the affinity of the ligand towards
ERα.
FP-based ERα receptor affinity detection coupled
on-line to gradient HPLC
Coupling of the homogeneous ERα FP RAD assay to
HPLC was performed in a similar way to that described
Fig. 2 Schematic overview of the ERα fluorescence polarization
receptor affinity detection (RAD) system in high-resolution screening
(HRS) mode. Samples are injected with an autoinjector (A.I.) and are
separated using a gradient reversed-phase high-performance liquid
chromatography (HPLC) system controlled by P1 and P2, HPLC
gradient pumps. After the column the flow is split by a flow spitter, S
(split ratio 1:9). HPLC elution is monitored by UV or fluorescence
detection. A makeup gradient, controlled by makeup gradient pumps
P3 and P4, is introduced and eluting compounds are mixed in the first
reaction coil with ERα delivered by superloop-1 (SL-1). In the second
reaction coil, the probe ligand E2-F is added to the mix by superloop-
2 (SL-2). ERα affinity detection is performed using a fluorescence
detector (FLD). In FIA mode the samples are delivered directly by a
carrier solution into the bioassay
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recently by Kool et al. [14] for a Cyt P450 affinity assay.
When operating the ERα FP RAD system in HPLC mode
(Fig. 2), two pumps were used to control the HPLC gra-
dient and, directly after the HPLC column, the HPLC
eluent was split into a 1:9 ratio where nine-tenths of the
flow was directed to either an UV (Agilent 1100 series) or
fluorescence detector (Agilent 1100 series). The choice of
detector depended on the compounds to be analyzed. To
compensate for increasing the organic modifier concen-
trations before the delivery of the HPLC eluent to the ERα
FP RAD system, two pumps were used to supply a makeup
flow consisting of an opposite H2O/MeOH gradient com-
pared with the HPLC gradient in order to keep the MeOH
concentration in the assay constant at 10%. One-tenth of the
total makeup flow was combined with one-tenth of the
HPLC eluent and this flow was directed to the ERα FP
RAD at 160 μl/min. The remaining part of the flow in the
ERα FP RAD was the same as described above, with the
exception that the HPLC flow combined with the makeup
flow replaced the carrier solution flow.
For HPLC analysis, test compounds were dissolved in 50%
MeOH in water. For coumestrol, a linear gradient from 75%
MeOH to 99% MeOH in 7.5 min, constant for 47.5 min, and
back to 75% MeOH in 1 min was applied. The total flow of
the HPLC pumps was 162 μL/min and detection took place
by measuring UV at 254 nm. For the mixture containing
estriol, coumestrol, coumarol, E2 and zearalenone, constant
elution at 55% MeOH for 40 min, followed by a linear
gradient from 55%MeOH to 70%MeOH in 50 min, constant
for 50min, and back to 55%MeOH in 1 min was applied. The
total flow rate of the HPLC pumps was 229 μL/min and
detection took place using UVat 254 nm. For zearalenone and
its cytochrome P450-generated metabolites, a linear gradient
from 40% MeOH to 99% MeOH in 40 min, constant for
30 min, and back to 40% MeOH in 1 min was applied. The
total flow rate of the HPLC pumps was 162 μL/min and
detection took place using a fluorescence detector (λex
279 nm; λem 440 nm). All HPLC separations were carried
out on a 150×4.6 mm i.d. Luna C18(2) column protected
with a 2.0×5.0 mm i.d. C18 guard column (Phenomenex,
Amstelveen, The Netherlands). The HPLC column was
thermostated at 25 °C.
Results and discussion
The aim of this research was to combine a recently devel-
oped on-line FP detector cell (Kool et al. [20]) with high-
resolution screening (HRS) technology to develop a
sensitive screening platform for measuring the ERα
affinities of individual components in mixtures of com-
pounds without incurring interference from autofluores-
cence at wavelengths below 450 nm. We first synthesized a
suitable tracer compound and used this tracer to set up a
FP-based ERα binding assay in FP microplate reader
format. The optimized assay conditions for the FP micro-
plate reader format were transferred to an on-line bioassay
format in FIA mode. In this mode we subsequently opti-
mized the on-line assay conditions and validated them by
measuring IC50 values of known estrogenic compounds in
both microplate reader format and in FIA mode. We used
the optimized conditions in FIA mode to couple the ERα
bioassay on-line to a gradient HPLC system. In HPLC
mode we measured the ERα bioaffinities of different estro-
genic compounds and screened mixtures with five known
estrogenic compounds. Finally, we measured the individual
ERα bioaffinities of zearalenone and its metabolites
generated off-line by Cyt P450 in HPLC mode.
Synthesis of E2-F
Synthesis of the fluorescein-labeled derivative E2-F (Fig. 1)
was relatively straightforward. The synthetic route described
in this paper makes use of readily available chemicals. The
yields of intermediate products are relatively high except for
the product of the second reaction step, in which compound
2 is converted into 3. However, the required reactants for this
step are not expensive, which makes it possible to perform
this step on a large scale. The last and most expensive step
involving the coupling of 5-FITC to 7 still gives a yield of
75% after extraction and purification. Overall, we conclude
that this synthetic protocol offers a good alternative to the
synthetic scheme described in the literature [7, 19] that is
used to produce a fluorescein-labeled E2 derivative. We
describe a seven-step synthesis with an overall yield of 12%
compared with an eight-step synthesis in the literature with a
total yield of 7% [19].
To test whether the newly synthesized E2-F had affinity
for the ERα, a competitive binding curve for E2-F and ERα
LBDwas constructed (data not shown) using the coumestrol-
based microplate reader assay described by Gurer-Orhan
et al. [6]. E2-F was able to displace coumestrol from the
ERα binding site, resulting in an IC50 value of 28.2 nM.
This value is consistent with KD values found for similar
tracers, which were also in the nanomolar range [7, 19].
Therefore, we concluded that the synthesized E2-F had
affinity for the ERα and could be used to further develop a
FP-based microplate reader assay.
FP-based microplate reader assay of ERα affinity
The first step in the optimization of the FP-based micro-
plate reader ERα affinity assay was the investigation of the
influence of E2-F tracer concentration upon the FP-based
microplate reader assay response of ERα-ligands. To
achieve this we compared the FP signal obtained with 0%
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ligand displacement (no E2 present in the incubation) with
the FP signal with 100% ligand displacement (33.3 μM E2
present in the incubation). We also incubated different
concentrations of E2-F tracer with a fixed concentration of
ERα. The difference in fluorescence polarization [ΔFP in
millipolarization (mP)] was plotted against decreasing E2-F
concentrations (Fig. 3). From this figure it can be seen that
ΔFP increases with decreasing tracer E2-F concentrations
until it reaches a maximum at 166 nM. However, it should
also be noted that when the E2-F tracer concentration
decreases, the error bars increase, which means that the S/N
ratios become worse. For the ERα-binding assay, we
preferred to use a tracer concentration which is not too
high, because high tracer concentrations make it necessary
to use high concentrations of test compounds as well in
order to displace the tracer from the receptor, which results
in a decreased assay sensitivity. However, if we use a tracer
concentration which is too low, this will also result in
unfavorable S/N ratios. Based upon our results and the KD
values of 10.4 and 3 nM found by Ohno et al. [19] and
Parket et al. [7] respectively for structurally similar
fluorescein-labeled E2 derivatives, we decided to use an
E2-F tracer concentration of 83.3 nM for further optimiza-
tion experiments. At this concentration the ERα response
was high, which makes it easier to detect the tracer–
receptor complex in an on-line assay, with a low S/N ratio,
and with the concentration in the same range as the KD
value, which makes it possible to determine IC50 values
more accurately.
The second step in the optimization process was the
investigation of the influence of the detergent Tween 20 and
the solvents methanol (MeOH), acetonitrile (ACN) and
isopropanol (iPrOH) on assay performance using the
conditions as optimized in the previous step. Experiments
revealed that Tween 20 was not compatible with the ERα
FP assay (data not shown). At very low concentrations
(0.04%), the presence of Tween 20 in the assay caused a
large decrease in ΔFP between E2-F bound to ERα (0%
displacement; absence of E2) and E2-F displaced by
33.3 μM E2 (100% displacement). Although the addition
of Tween 20 can give improved resolution in terms of peak
width [25], we decided not to use it due to the large
decrease in the difference in polarization. In Fig. 4, the
effect of increasing concentrations of MeOH, ACN and
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Fig. 3 FP-based microplate reader tracer concentration optimization.
Incubations in the presence of ERα ligand E2 (33.3 μM; equal to
100% tracer displacement) were compared with incubations without
E2 (equal to 0% tracer displacement) at decreasing E2-F tracer
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Fig. 4 FP-based microplate
reader solvent optimization.
Incubations in the presence of
ERα ligand E2 (33.3 μM; equal
to 100 % tracer displacement)
were compared with incubations
without E2 (equal to 0% dis-
placement) at increasing MeOH,
ACN and iPrOH concentrations
at an E2-F concentration of
83.3 nM
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iPrOH on ΔFP is shown. It can be seen from this figure
that ΔFP decreases with increasing organic modifier con-
centrations. ΔFP decreased to almost zero for ACN at the
highest concentration. For MeOH and iPrOH, however, a
signal difference between the E2-F bound to ERα and
displaced by E2 could still be observed at the highest
modifier concentration. Oosterkamp et al. [10] have stated
that denaturation of the estrogen receptor occurs upon
prolonged contact with organic solvents such as MeOH and
ACN. It is therefore reasonable to assume that when the
organic modifier is present at higher concentrations, the
denaturation process for ERα LBD increases, which results
in smaller fluorescence polarization signal differences.
FP-based ERα receptor affinity detection (RAD)
in flow-injection analysis (FIA) mode
The optimized microplate reader assay conditions were
transferred to the on-line ERα RAD system in FIA mode
(Fig. 2). In this system, compounds introduced by a carrier
solution are allowed to bind to the ERα LBD in a first
reaction coil, and the E2-F tracer is introduced after this
coil. The tracer compound can interact with the unbound
receptor in a second reaction coil and detection takes place
after the second reaction coil using FP detection. In a FIA
setup, carrier solution replaces the gradient HPLC system,
thereby allowing the direct injection of compounds and the
optimization of on-line assay conditions before final on-line
coupling to HPLC. The influence of the ERα LBD and E2-
F tracer concentrations and the corresponding excitation
and emission wavelengths were investigated in FIA mode
in order to optimize the performance of the FP ERα RAD
system. The influences of ACN and MeOH, later used in
HPLC mode too, on the FP ERα RAD system performance
were also tested in the FIA mode. All measurements were
performed in duplicate.
ERα LBD and E2-F tracer optimization Different receptor
concentrations (ERα LBD) were tested in combination with
different tracer concentrations (E2-F) by varying the flows
of SL-1 (containing 10 nM ERα in binding buffer) and SL-
2 (containing 1 μM E2-F in binding buffer). The total flow
rate was kept constant by introducing a compensating
superloop containing only binding buffer. Water was used
as carrier solution in order to inject 10 μL 100 μM E2 in
50% MeOH samples (100% ligand displacement) in
duplicate followed by 10 μL injections of 50% MeOH
(0% displacement) at a flow rate of 250 μL/min. The results
obtained with these experiments are depicted in Fig. 5. This
figure shows that as the E2-F tracer concentration increases
the FP signal increases too, until it reaches a maximum.
Using the present FIA FP ERα RAD setup, we were able to
determine the KD and maximum response (Rmax) values for
the E2-F tracer compound (Table 1) at different ERα
concentrations. The KD values found were of the same
order as observed by Ohno et al. [19] and Parker et al. [7]
for an analogous FP tracer compound. It can be seen that
Rmax increases linearly with higher ERα concentrations, as
was expected. Based upon these results, we conclude that
the FP ERα RAD in FIA mode worked well, and we
continued by investigating the influence of the organic
modifier upon the assay performance.
Organic modifier concentration Although we also investi-
gated the influence of iPrOH upon the ERα bioaffinity
assay performance in the FP-based microplate reader
format, we decided to evaluate only MeOH and ACN in
FIA mode based upon the fact that we planned to use only
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Fig. 5 Determination of KD and maximum response (Rmax) for E2-F
in FIA mode. Different concentrations of E2-F were incubated with
three different ERα concentrations
Table 1 KD and maximum response (Rmax) determination for E2-F in
FIA mode
[ERα] (nM) KD (nM) Rmax (AUC)
a
0.7 43.6±12.4 2.17×106
1.5 26.4±5.0 4.04×106
3.0 34.5±5.3 9.38×106
aRmax was determined by integrating the decrease in FP signal, and
arbitrary units were chosen to display this decrease
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Fig. 6 Effect of MeOH and ACN reaction coil concentrations upon
the assay performance in FIA mode. The S/N ratios of the E2
injections equalling 100% tracer displacement are displayed
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these two solvents in HPLC mode. Different concentrations
of MeOH and ACN were used as the carrier solution in
order to inject 10 μL 100 μM E2 ligand in 50% MeOH
samples (100% ligand displacement) in duplicate followed
by 10 μL injections of 50% MeOH (0 μM E2 ligand; 0%
displacement) into the system. The ERα LBD concentra-
tion in the second reaction coil was 2.7 nM, the E2-F tracer
concentration 110 nM and the total flow rate 300 μL/min.
Increasing the concentration of MeOH decreased the S/N
ratio in FIA mode (Fig. 6). A similar effect was observed
with ACN. A possible explanation for this decreasing effect
is the partial denaturation of the estrogen receptor due to the
presence of high concentrations of organic modifier.
Oosterkamp et al. [10] have described this phenomenon
during the optimization of the ERα coumestrol-based RAD
system when a decrease in response was observed upon the
contact of the ERα with organic solvents such as MeOH
and ACN. One advantage of a higher organic modifier
concentration is that higher flow rates can be used in HPLC
gradients, which may result in shorter analysis times and
higher resolutions. Another advantage is that high concen-
trations of organic modifier prevent lipohilic compounds
from adsorbing to the walls of the reaction coils and other
tubing, which may increase resolution. Based upon our
results during FP FIA setup, we concluded that both MeOH
and ACN might be used in the on-line gradient HPLC
system.
Excitation and emission wavelengths When the excitation
and emission wavelengths were varied, the optimal FP
signal responses in FIA mode were obtained at an exci-
tation wavelength of 498 nm and an emission wavelength
Table 2 IC50 values determined in FIA mode and in microplate reader assay format
Compound FIA mode IC50 (M ± SEM; n=3) Microplate setup IC50 (M ± SEM; n=3) Literature data IC50 (M)
DES 6.9±0.3×10−9 6.1±0.6×10−9 3.5×10−9 a
Tamoxifen 1.2±0.1×10−7 1.3±0.4×10−7 1.9×10−7 a
Coumestrol 1.8±0.2×10−7 2.5±0.3×10−7 3.6×10−7 b
E2 6.7±0.8×10−9 3.3±0.3×10−9 5.6×10−9 a
EE2 1.6±0.2×10−9 3.5±0.8×10−9 2.3×10−9 b
IC50 values of five estrogenic compounds towards the ERα, as measured with the RAD system in FIA mode and with the microplate reader assay
format. Data from literature a [7], b [26] are also shown. DES, diethylstilbestrol; E2, 17β-estradiol; EE2, 17α-ethinyl estradiol
Fig. 7 ERα FP RAD trace of a mixture of five estrogenic compounds
injected into the ERα FP RAD HPLC system (injected compounds are
as follows: estriol (1) [3.75 nmol; 49.5 min], coumestrol (2)
[3.75 nmol; 53.7 min], coumarol (3) [37.5 nmol; 80.4 min], 17β-
estradiol (4) [3.75 nmol; 102.8 min] and zearalenone (5) [12.5 nmol;
112.5 min]
Anal Bioanal Chem (2008) 390:1987–1998 1995
of 522 nm (data not shown). These wavelengths were
therefore used to further optimize the on-line FP system in
FIA mode.
Competitive receptor binding curves To validate the ERα
FP RAD system, competitive binding curves for five known
estrogenic test compounds—DES, E2, EE2, tamoxifen and
coumestrol—were constructed using the FP-based micro-
plate reader assay, and these values were compared with the
IC50 values obtained using the ERα FP setup in FIA mode.
The ERα LBD concentration was 1.6 nM and the E2-F
tracer concentration was 80 nM for the microplate reader
assay. In FIA mode, the ERα LBD concentration in the
second reaction coil was 2.7 nM and the E2-F concentration
was 110 nM. All five test compounds displayed sigmoidal
concentration–response curves during both the microplate
reader setup and in FIA mode, and from these curves we
were able to determine the IC50 values (Table 2). The
values found in the two different setups were similar for
each individual compound and in agreement with values
obtained from the literature [7, 26]. We thus demonstrated
that the FP-based microplate reader assay and the ERα FP
setup in FIA mode could be employed to determine the
IC50 values of a wide range of typical ERα-binding ligands
accurately. The next step in the process of developing the
HRS platform was to couple the FIA ERα FP system to a
gradient HPLC system on-line.
FP-based ERα receptor affinity detection coupled
on-line to HPLC
Following assay optimization in the microplate reader and
FIA modes, the ERα FP RAD assay was coupled on-line to
Fig. 8a–b a HPLC FLD chromatograms of zearalenone (Z) incubated
for 0 and 120 min with PB-induced rat liver microsomes. M1, M2 and
M3 are metabolites formed during the 120-min incubation period. b
The corresponding ERα FP affinity traces. The structure of zearale-
none is depicted in the figure
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gradient HPLC. In this HRS setup the flow eluting from an
HPLC column was coupled directly to the FP RAD system,
which enables compound separation prior to the screening
of individually eluting compounds for their ERα affinities.
This allowed us to screen for compounds with ERα affin-
ities in mixtures. To test the performance of the on-line HRS
FP ERα system, different concentrations of the phytoes-
trogen coumestrol were injected first. A negative peak in the
ERα bioaffinity trace was observed at a retention time of
40 min, which is the exact time when coumestrol eluted
from the HPLC column (data not shown). As expected, the
negative bioaffinity peaks became larger upon injections of
higher concentrations of coumestrol. The highest negative
peaks were observed when all of the E2-F was displaced by
coumestrol. Higher concentrations of coumestrol only
caused more tailing of the bioaffinity peaks. These measure-
ments illustrate that the ERα bioaffinity of the phytoestro-
gen coumestrol could be measured sensitively and
efficiently with the new E2-F based HRS ERα FP system,
which is not possible due to the occurrence of autofluor-
escence using the coumestrol-based ERα HRS system
developed by Oosterkamp et al. [10].
Representative superimposed chromatograms of different
concentrations of a mixture of five known estrogenic com-
pounds—coumestrol, coumarol, estriol, 17β-estradiol and
zearalenone—are depicted in Fig. 7. Although some baseline
drift in time is observed over two hours, it is quite possible to
detect the ERα bioaffinities of all five individual peaks in the
mixture. The explanation for the baseline drift is most likely
that the post-column makeup HPLC gradient does not totally
compensate for the effect of variations in the organic modifier
concentration. The FP ERα RAD system is sensitive to
changes in the organic modifier concentration, as shown
during FIA optimization, and this can lead to baseline drifts.
To illustrate another application of the on-line HRS ERα
FP system, metabolites of the phytoestrogen zearalenone,
which were anticipated to show affinity for the ERα, were
analyzed in the present FP-based HRS ERα system. For this
purpose, zearalenone was metabolized by phenobarbital (PB)-
induced rat liver microsomes in an off-line fashion, followed
by analysis with the FP-based HRS system. The results are
depicted in Fig. 8. The UV trace of the t=0 min incubation
shows that zearalenone (Z) elutes at 51.4 min. The
corresponding bioaffinity trace shows that zearalenone has
affinity for ERα. The FLD trace of the t=120 min incubation
shows that zearalenone is metabolized by rat liver micro-
somes into at least three major metabolites (M1: 33.5, M2:
39.5 and M3: 43.2 min). The corresponding bioaffinity trace
demonstrates that all three major metabolites (M1–3) have
affinity for ERα. LC/MS measurements were performed to
identify the three major metabolites. M1 had a molecular ion
at an m/z value of 333, which likely corresponds to a
monohydroxylated zearalenone metabolite. M2 had a mo-
lecular ion at an m/z value of 317, which is the exact same
m/z value as that of zearalenone itself. This can be explained
by the relocation of the double carbon–carbon bond next to
the aromatic ring. However, more research must be
performed to confirm this. M3 had a molecular ion at an
m/z value of 319, which corresponds well to the m/z value of
the zearalenone metabolite zearalenol described in the
literature [27]. The metabolism of zearalenone in vitro by
rat liver microsomes has been described very recently by
Pfeiffer et al. [28], and they confirm the findings of M1 and
M3. The present Cyt P450 metabolism experiment illustrates
that it is possible to screen metabolic mixtures of phytoes-
trogenic compounds for ERα affinity using the present FP-
based HRS ERα setup. However, no further structural
elucidation of the zearalenone metabolites has been per-
formed, because the goal of the present experiment was only
to show that the on-line FP HRS ERα assay can be used to
screen for parent compounds and metabolites of phytoes-
trogens with ERα affinity.
We conclude that we succeeded in developing, for the first
time, an on-line FP-based HRS platform to screen for ERα
affinity using the novel on-line FP detector cell recently
described in a FIA mode by Kool et al. [20]. The sensitivity
of the FP-based HRS platform is comparable to that of the
coumestrol-based HRS platform, and no interference from
fluorescence was observed at wavelengths below 450 nm.
The novel on-line FP detector cell can in principle be
applied to other HPLC-based bioaffinity assays which
require FP detection. The present HRS ERα FP system
offers a novel technology for investigating the metabolic
profiles of drugs and other compounds such as phytoes-
trogens which cannot be measured by the coumestrol-based
HRS system due to the occurrence of autofluorescence
from the test compounds.
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